These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15285814)

  • 1. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: results from the X-ACT trial.
    Reddy GK
    Clin Colorectal Cancer; 2004 Jul; 4(2):87-8. PubMed ID: 15285814
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in people with resected stage III colon cancer.
    Lamberti C; Sauerbruch T; Glasmacher A
    Cancer Treat Rev; 2005 Dec; 31(8):648-52. PubMed ID: 16289340
    [No Abstract]   [Full Text] [Related]  

  • 3. Redefining adjuvant chemotherapy in patients with stage III colon cancer: X-ACT trial.
    Glen H; Cassidy J
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):547-51. PubMed ID: 18402521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
    Scheithauer W; McKendrick J; Begbie S; Borner M; Burns WI; Burris HA; Cassidy J; Jodrell D; Koralewski P; Levine EL; Marschner N; Maroun J; Garcia-Alfonso P; Tujakowski J; Van Hazel G; Wong A; Zaluski J; Twelves C;
    Ann Oncol; 2003 Dec; 14(12):1735-43. PubMed ID: 14630678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.
    Cassidy J; Douillard JY; Twelves C; McKendrick JJ; Scheithauer W; Bustová I; Johnston PG; Lesniewski-Kmak K; Jelic S; Fountzilas G; Coxon F; Díaz-Rubio E; Maughan TS; Malzyner A; Bertetto O; Beham A; Figer A; Dufour P; Patel KK; Cowell W; Garrison LP
    Br J Cancer; 2006 Apr; 94(8):1122-9. PubMed ID: 16622438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine as adjuvant treatment for stage III colon cancer.
    Twelves C; Wong A; Nowacki MP; Abt M; Burris H; Carrato A; Cassidy J; Cervantes A; Fagerberg J; Georgoulias V; Husseini F; Jodrell D; Koralewski P; Kröning H; Maroun J; Marschner N; McKendrick J; Pawlicki M; Rosso R; Schüller J; Seitz JF; Stabuc B; Tujakowski J; Van Hazel G; Zaluski J; Scheithauer W
    N Engl J Med; 2005 Jun; 352(26):2696-704. PubMed ID: 15987918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xeloda in Adjuvant Colon Cancer Therapy (X-ACT) trial: overview of efficacy, safety, and cost-effectiveness.
    Twelves CJ
    Clin Colorectal Cancer; 2006 Nov; 6(4):278-87. PubMed ID: 17241512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On prejudice and facts and choices.
    Köhne CH; Folprecht G
    Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
    [No Abstract]   [Full Text] [Related]  

  • 11. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
    Twelves C; Scheithauer W; McKendrick J; Seitz JF; Van Hazel G; Wong A; Díaz-Rubio E; Gilberg F; Cassidy J
    Ann Oncol; 2012 May; 23(5):1190-1197. PubMed ID: 21896539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial.
    Aparicio T; Francois E; Cristol-Dalstein L; Carola E; Maillard E; Paillaud E; Retornaz F; Faroux R; André T; Bedenne L; Seitz JF
    Dig Liver Dis; 2016 Feb; 48(2):206-7. PubMed ID: 26748426
    [No Abstract]   [Full Text] [Related]  

  • 14. Adjuvant therapy in colon cancer: which treatment in 2005?
    Di Costanzo F; Doni L
    Ann Oncol; 2005 May; 16 Suppl 4():iv69-73. PubMed ID: 15923433
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant therapy for stage II and III colorectal cancer.
    de Gramont A; Tournigand C; André T; Larsen AK; Louvet C
    Semin Oncol; 2007 Apr; 34(2 Suppl 1):S37-40. PubMed ID: 17449351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
    Nikolic-Tomasevic Z; Jelic S; Cassidy J; Filipovic-Ljeskovic I; Tomasevic Z
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):594-602. PubMed ID: 16044340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in research on capecitabine as adjuvant treatment for colon cancer after radical resection].
    Zhang SZ
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):801-3. PubMed ID: 21223682
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
    Schmoll HJ; Twelves C; Sun W; O'Connell MJ; Cartwright T; McKenna E; Saif M; Lee S; Yothers G; Haller D
    Lancet Oncol; 2014 Dec; 15(13):1481-1492. PubMed ID: 25456367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Capecitabine].
    Yamaguchi K; Shimamura T; Tada M
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.